QBiotics signs supply, marketing and distribution agreement with Virbac for canine cancer treatment

August, 2018

QBiotics Group has signed an agreement with Virbac, one of the largest dedicated animal health companies globally, to supply, market and distribute its canine anticancer pharmaceutical, tigilanol tiglate.

Under the terms of the agreement, Virbac is granted the right to market and distribute tigilanol tiglate, QBiotics' anticancer pharmaceutical, to veterinary markets in the USA, Switzerland, Norway, UK and EU on receipt of marketing authorisation. There is the potential of future expansion to other focus territories including Australia, New Zealand and Canada.

This is a significant milestone for QBiotics as we approach commercialisation of our first veterinarian pharmaceutical.

The canine mast cell tumour pivotal efficacy trial has been completed for registration in the USA, Europe and the UK. Final submission to the USA FDA-CVM and European EMA for tigilanol tiglate is planned for October 2018. To date, there are only a very small number of registered treatments for cancer in companion animals, providing a significant opportunity for tigilanol tiglate in this growing market.

Further information on the QBiotics Virbac Agreement Update (PDF)